Skip to main content
Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

From
To
  • Default content image

    The Michael J. Fox Foundation’s Efforts to Develop New Tools for Understanding LRRK2 Biology and the Role of LRRK2 in Parkinson’s Disease Pathology

    As the greatest known genetic contributor to Parkinson's disease (PD), the leucine-rich repeat kinase 2 (LRRK2) gene and protein are targets of interest for Parkinson’s disease research and…

  • Default content image

    Characterization of a humanized A53T alpha-synuclein (aSyn A53T KI) and alpha-synuclein KO (aSyn KO) models

    Mutations and multiplications in the SNCA gene encoding the alpha-synuclein protein are linked to an autosomal dominant form of Parkinson’s disease (PD). One such mutation is the alanine-to-threonine…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…

  • Default content image

    LRRK2 Detection in PBMC Consortium

    The “LRRK2 Detection in PBMC Consortium” is a pre-competitive collaboration between MJFF and select industry partners with the goal of optimizing the measurement of pLRRK2 in human PBMCs. MJFF…

  • Default content image

    Cell Line Resources from Parkinson’s Progression Markers Initiative (PPMI) Participants

    The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal observational study conducted at over thirty international sites that collects data and biospecimens from idiopathic Parkinson…

  • Default content image

    Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents

    Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting approximately one-percent of the population over the age of sixty. Although many animal models have been…

  • Default content image

    The Michael J. Fox Foundation’s Efforts to Generate, Characterize, and Promote the Use of a Variety of Preclinical Models of Parkinson’s Disease

    Preclinical models are a necessary tool for investigating the pathogenesis and potential therapeutic strategies for diseases like Parkinson’s disease (PD). As the precise etiology of PD is currently…

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

From
To

No results were found.

Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.